| 000 | 01404 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250511181104.0 | ||
| 264 | 0 | _c19920511 | |
| 008 | 199205s 0 0 eng d | ||
| 022 | _a0312-5963 | ||
| 024 | 7 |
_a10.2165/00003088-199222030-00004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCutler, N R | |
| 245 | 0 | 0 |
_aPharmacokinetics and dose proportionality of D2-agonist MK-458 (HPMC) in parkinsonism. _h[electronic resource] |
| 260 |
_bClinical pharmacokinetics _cMar 1992 |
||
| 300 |
_a223-30 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 |
_aDopamine Agents _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLactose _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylcellulose _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOxazines |
| 650 | 0 | 4 |
_aParkinson Disease _xblood |
| 650 | 0 | 4 | _aTablets |
| 700 | 1 | _aReines, S A | |
| 700 | 1 | _aMcLean, L F | |
| 700 | 1 | _aSramek, J J | |
| 700 | 1 | _aPorras, A G | |
| 700 | 1 | _aHand, E L | |
| 773 | 0 |
_tClinical pharmacokinetics _gvol. 22 _gno. 3 _gp. 223-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00003088-199222030-00004 _zAvailable from publisher's website |
| 999 |
_c1354953 _d1354953 |
||